Forte Biosciences (FBRX) Short-term Investments (2023 - 2026)
Forte Biosciences (FBRX) posted quarterly Short-term Investments of $36.1 million for Q4 2024, up 261.68% quarter-over-quarter from $10.0 million in Q2 2023.
Powered by 
Analysis
Forte Biosciences (FBRX) Short-term Investments (2023 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has reported Short-term Investments for 2 consecutive years, with $36.1 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Short-term Investments changed N/A year-over-year to $36.1 million; the TTM figure through Dec 2024 stood at $36.1 million (changed N/A YoY), while the FY2024 annual figure was $36.1 million, changed N/A from the prior year.
- Short-term Investments rose to $36.1 million in Q4 2024 per FBRX's latest filing, from $10.0 million in the prior quarter.
- Across five years, Short-term Investments topped out at $36.1 million in Q4 2024 and bottomed at $10.0 million in Q2 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | Forte Biosciences | 1.58 Bn | 1.23 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 148.83 Mn |
| Dec 31, 2024 | 36.12 Mn |
| Jun 30, 2023 | 9.99 Mn |